MEIP News and Press, MEI Pharma Inc.

2024-07-01 14:18:31 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Every investment category must answer the big question, why? For undervalued biotech stocks , it comes down to advantaging a supremely relevant sector without paying full price. Of cour...

2024-05-09 17:28:13 ET More on MEI Pharma MEI Pharma shelves plans for a second return of capital Seeking Alpha’s Quant Rating on MEI Pharma Historical earnings data for MEI Pharma Financial information for MEI Pharma Read the full article on...

-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients -- -- Board of Directors Unanimously Aligned on Prioritizatio...

2024-04-11 14:17:44 ET More on MEI Pharma Seeking Alpha’s Quant Rating on MEI Pharma Historical earnings data for MEI Pharma Financial information for MEI Pharma Read the full article on Seeking Alpha For further details see: MEI Pharma she...

– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritizing Measured Investment, Extending Operational Runway – MEI Pharma, Inc. ...

– Cohort 1 Exceeds Predetermined Non-Progression Threshold in the Ongoing Phase 1b Study – – ME-344 in Combination with Bevacizumab was Generally Well-tolerated with no Evidence of Overlapping Toxicity – – MEI to Continue Advancing ME-344 via Dev...

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David Urso, president and chief executive officer of MEI Pharma, will participate in a firesi...

– Enrollment Initiated in 12-Patient Expansion Cohort Evaluating Voruciclib Plus Venetoclax in Ongoing Phase 1 Study – – Anti-leukemic Activity Across Multiple Heavily Pretreated Patients Demonstrated Along with Anticipated Decreases in Mcl-1 – –...

2024-03-14 14:54:38 ET More on Impel NeuroPharma, Infinity Pharmaceuticals, etc. Sorrento wins DoJ’s venue-based challenge to bankruptcy filing Scilex and Sorrento settle with Virpax and its founder Anthony Mack Financial information for Impel NeuroPharma ...

2024-02-20 17:42:00 ET More on MEI Pharma Seeking Alpha’s Quant Rating on MEI Pharma Historical earnings data for MEI Pharma Read the full article on Seeking Alpha For further details see: MEI Pharma files for $100M mixed shelf